Fujian Provincial
Fuzhou, Fujian, 350001, China
NCT Number: NCT03791606
A retrospective, observational study included all consecutively critically ill patients undergoing percutaneous coronary intervention(PCI) at intensive care unit (ICU) in Fujian Provincial Hospital from January 1st 2012 to December 31st 2018. The aim was to determine the incidence,risk factors,prophylactic strategy and outcomes of CI-AKI in critically ill patients undergoing PCI.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Fuzhou, Fujian, 350001, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
an absolute SCr increase ≥0.3 mg/dL or a relative increase in SCr ≥50% within 48 hours of contrast medium exposure
Time frame: 1 year
congestive heart failure [CHF], bleeding, stroke, reinfarction, stent thrombosis, required renal replacement therapy, length of hospital stay, hospital costs, and mortality
Time frame: 1 year
mortality,stent restenosis, recurrent myocardial infarction, target vessel revascularization,stroke,bleeding,required renal replacement therapy
Kaiyang Lin
Other
Risk Factors,PREvention and outComes for Contrast-Induced Acute Kidney Injury in patientS undErgoing Percutaneous Coronary Intervention at Intensive Care Unit:a Single-center Cohort Study(PRECISE-ICU)
Acronym: PRECISE-ICU
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07020130
CIN
Fuzhou, Fujian, China
View Trial DetailsNCT04809727
CIN, Cancer of Cervix
Tanta, Gharbia Governorate, Egypt
View Trial DetailsNCT00339989
CIN, Cervical Cancer
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT03239223
CIN, Cervical Cancer
Los Angeles, California, United States
View Trial Details